Overview of the three-year work programme (2010–2012) Rosemary de Sousa, Roland Simon, Paul Griffiths 30th ScC meeting, June 2009

Triennial and annual work plans Three-year strategy (2010–2012) will be implemented through three annual work plans 2010–2012 WP still to be formally adopted by the Management Board – modification possible 2010 WP will need to be drafted for approval at the December MB (after consultation)

Strategic overview Coherence and continuity (2010–2012 built on progress made in 2007–2009) Keep pace with the changing nature of the European drugs problem and emerging information needs Guided by: recast regulation, new EU action plan Make best use of scarce and limited resources Rationalisation of current work Refine dissemination strategy Encourage and support development of exchange platform Find room for some new developmental areas Synergy with national, regional and international activities

Broader context Commitment to annual reporting Founding regulation basis for work – recast to regulation in 2007 gave more emphasis to new trends identification and dissemination of best practice polydrug use including combined use of licit and illicit substances Supply information has always been collected but need to scale- up activities EU – drug strategy and action plan(s) have become increasingly important EU enlargement and neighbourhood policy remains an important factor

Challenges of working in a growing family Currently reporting All EU Member States Norway by special arrangement Candidate countries – Croatia and Turkey The Russian Federation, Ukraine and other countries have growing interest in EMCDDA work The needs of countries and reporting ability varies considerably Quality control and the analysis of data can raise political as well as scientific issues

The new work programme… moving forward

Overview of this presentation EPI (Paul) Monitoring drug situation Risk assessment and trends RES (Roland) Monitoring interventions, responses and solutions Improving capacity to evaluate policies and interventions Disseminate best practice Communication (Rosemary)

Strategic framework for monitoring drugs in Europe Organised around 4 pillars with cross-cutting and developmental issues Focused, developmental and long-term vision Continue development of key areas Increased emphasis on best practice, quality of interventions and identifying solutions Limited number of strategically important new areas

WP schematic

Three-year work programme – main areas Monitoring the drug situation New trends and development Monitoring responses Best practices, standards and guidelines Goal Provide a sound evidence base for informed policies and action through developing and implementing high quality data collection tools that permit analysis of the drug situation, its impact and the tracking of trends over time

Area 1: Monitoring drug situation – themes Tools and process (1.1) Continuing improvements to data management procedures and processes Rationalisation of process Improvements to data resources Key indicators (1.2) Continued development and refinement (TDI, PDU) Better assessment and support Broader and improved analytical concepts More sensitivity to polydrug use, non-opiates and trends

Area 1 – themes (cont.) Developmental areas (1.3) Supply reduction Price purity, labs drug production – seizures, forensic science, market analysis, reference group Prisons Analysis (1.4) More emphasis on scientific publications Modelling and transversal analysis with RES Joint working and analytical groups (DatLab) Global perspective

Three-year work programme – main areas Monitoring the drug situation New trends and development Monitoring responses Best practices, standards and guidelines Goal To develop a more responsive system for monitoring drug use and the appearance of new psychoactive substances and provide increased understanding of emerging and new trends of drug use to facilitate early responses to potential threats

Area 3: New trends and developments – themes Risk assessment (3.1) Continue to implement Coherence with broader strategy Improve database – forensic science links Collaboration with Europol and EMEA Review? Emerging trends (3.2) Rapid response team Proactive case study approach Trend spotting and new data sources (pilot)

Three-year work programme – main areas Monitoring the drug situation New trends and development Monitoring responses Best practices, standards and guidelines Goal Continue to monitor the availability, accessibility and quality of responses to drug use in Europe through a set of systematic, well-defined and analytically relevant indicators

Area 2: Monitoring interventions Data collection (2.1) Continue data collection procedures Monitor research literature (especially programme effectiveness) Analyse complementary data collection mechanisms Keep in contact with scientific/public debate on interventions (Re-)Define the set up response indicators (2.2) 1.Drug policy and legal interventions 2.Prevention and early intervention 3.Treatment, harm reduction, health and social interventions 4.Supply reduction interventions 5.Drug-related cost and expenditure

Area 2: Monitoring interventions (cont.) Methodological development (2.3) More cross analyses between EPI and RES data sets Work on the assessment of policy, legal, financial and organisational models Develop intervention profiles Develop quality standards for interventions Develop economic modelling of drug issues More sensible monitoring of service provision for high-risk populations

Three-year work programme – main areas Monitoring the drug situation New trends and development Monitoring responses Best practices, standards and guidelines Goal Support the development of evidence-based actions, standards and guidelines for best practices and develop analytical tools to facilitate assessment of the impact and effectiveness of drug policy and interventions

Area 4: Best practices, standard and guidelines Monitor and support tools development to assess drug policy (4.1) Develop tools for assessment Expand public expenditure conceptually towards costs of interventions More analytical focus in ELDD Conceptually integrating drug policy, law, and public expenditure

Area 4: Best practices, standard and guidelines (cont.) Support good practice, guidelines and quality standards (4.2) Set up expert groups Define process for standards and guidelines Provide information on basic texts, standards and guidelines as required – taking technical requirements into account Work towards a better understanding of drug markets Develop partnership with Europol Integrate expertise and information from related fields

Keeping communication on target Timeliness Shortened production cycles where possible Inclusion of more topical information in reporting Getting the medium right: accessibility Web-based products Language issues Active communication: face-to-face Visits from policymakers Presentations at conferences Disseminating and valorising outputs Extent to which outputs are reaching their target audience Discuss increased involvement of national focal points in dissemination activities

Responding better to differentiated needs (1) Policymakers Multilingual policy summary accompanies all main products Continue to address topical issues of policy interest Tailored and rapid response to information requests that inform policy discussion Scientists and researchers Scientific Committee provides improved forum for dialogue with this target group Visibility increased through publishing in scientific journals Networking and training activities Assistance for secondary analysis of data sets Support for publishing scientific articles into languages other than English

Responding better to differentiated needs (2) Practitioners Further develop tools that allow information to be shared on what responses work (including Best practice portal) Bring together existing guidelines and standards Produce ‘evidence papers’ that review scientific literature in key intervention areas Citizens Awareness-raising products that coincide with specific calendar events Improve links to national and international sites with a signposting ‘Drug use in Europe’ web page Media Continue to build sound contacts with journalists and provide media-friendly information Work with national focal points to improve dissemination of EMCDDA results to national media

Questions and discussions